Literature DB >> 17631558

The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions.

Ayse Mavi1, Tevfik F Cermik, Muammer Urhan, Halis Puskulcu, Sandip Basu, Jian Q Yu, Hongming Zhuang, Brian Czerniecki, Abass Alavi.   

Abstract

UNLABELLED: The purpose of this prospective study was to investigate whether correlations exist between 18F-FDG uptake of primary breast cancer lesions and predictive and prognostic factors such as estrogen receptor (ER), progesterone receptor (PR), and C-erbB-2 receptor (C-erbB-2R) states.
METHODS: Before undergoing partial or total mastectomy, 213 patients with newly diagnosed breast cancer underwent 18F-FDG PET (5.2 MBq/kg of body weight). The maximum standardized uptake value (SUV) of the primary lesion was measured in each patient. Standard immunohistochemistry was performed on a surgical specimen of the cancer lesion to characterize the receptor state of the tumor cells. Pearson chi2 tests were performed on the cross-tables of different receptor states to test any association that may exist among ER, PR, and C-erbB-2R. Maximum SUV measurements for different receptor states were compared using factorial ANOVA in a completely random design.
RESULTS: After exclusion of certain lesions, 118 lesions were analyzed for this study. The mean maximum SUVs of ER-positive and ER-negative lesions were 3.03 +/- 0.26 and 5.64 +/- 0.75, whereas those of PR were 3.24 +/- 0.29 and 4.89 +/- 0.67, respectively, and those of C-erbB-2R were 4.64 +/- 0.70 and 3.70 +/- 0.35, respectively. Chi2 tests for ER and PR showed that if one is positive then the other tends to be positive as well (chi2 = 71.054, P < 0.01). For ER and C-erbB-2R states, if ER is positive, C-erbB-2R will more likely be negative (chi2 = 13.026, P < 0.01). No relationship was detected between PR and C-erbB-2R states (chi2 = 3.695, P > 0.05). ANOVAs showed that PR state alone (F = 0.095, P > 0.05) and C-erbB-2R state alone (F = 0.097, P > 0.05) had no effect on 18F-FDG uptake but ER state alone had an effect (F = 9.126, P < 0.01). ER and PR being together had no additional effect on 18F-FDG uptake. Our study also demonstrated that interactions exist between ER and C-erbB-2R state and between PR and C-erbB-2R state.
CONCLUSION: SUV measurements may provide valuable information about the state of ER, PR, and C-erbB-2R and the associated glucose metabolism as measured by 18F-FDG uptake of the primary breast cancer lesions. Such an association may be of importance to treatment planning and outcome in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631558     DOI: 10.2967/jnumed.106.037440

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  27 in total

1.  Screening for breast cancer should be an integral part of myocardial perfusion imaging.

Authors:  Jean Lette; François Lette
Journal:  Can J Cardiol       Date:  2009-07       Impact factor: 5.223

2.  MR imaging features of invasive breast cancer correlated with hormonal receptors: does progesterone receptor matter?

Authors:  J H Chen; O Nalcioglu; M Y Su
Journal:  Ann Oncol       Date:  2008-03-28       Impact factor: 32.976

3.  18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men.

Authors:  Gary A Ulaner; Jessica Juarez; Christopher C Riedl; Debra A Goldman
Journal:  J Nucl Med       Date:  2018-09-20       Impact factor: 10.057

4.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Authors:  David Groheux; Sylvie Giacchetti; Jean-Luc Moretti; Raphael Porcher; Marc Espié; Jacqueline Lehmann-Che; Anne de Roquancourt; Anne-Sophie Hamy; Caroline Cuvier; Laetitia Vercellino; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

5.  Can positron emission mammography help to identify clinically significant breast cancer in women with suspicious calcifications on mammography?

Authors:  Almir G V Bitencourt; Eduardo N P Lima; Bruna R C Macedo; Jorge L F A Conrado; Elvira F Marques; Rubens Chojniak
Journal:  Eur Radiol       Date:  2016-09-02       Impact factor: 5.315

6.  Strong association of epidermal growth factor receptor status with breast cancer FDG uptake.

Authors:  Joohee Lee; Eun Jeong Lee; Seung Hwan Moon; Seokhwi Kim; Seung Hyup Hyun; Young Seok Cho; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-09       Impact factor: 9.236

7.  Correlation between 18F-FDG Positron-Emission Tomography 18F-FDG Uptake Levels at Diagnosis and Histopathologic and Immunohistochemical Factors in Patients with Breast Cancer.

Authors:  Gamze Uğurluer; Sinan Yavuz; Züleyha Çalıkuşu; Ertuğrul Seyrek; Mustafa Kibar; Meltem Serin; Canan Ersöz; Orhan Demircan
Journal:  J Breast Health       Date:  2016-07-01

Review 8.  Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology.

Authors:  Muhammad Kashif Rahim; Sung Eun Kim; Hyeongryul So; Hyung Jun Kim; Gi Jeong Cheon; Eun Seong Lee; Keon Wook Kang; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2014-01-22

Review 9.  18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.

Authors:  Hossein Jadvar; Abass Alavi; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

10.  Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.

Authors:  Su Hyun Lee; Seunggyun Ha; Hyun Joon An; Jae Sung Lee; Wonshik Han; Seock-Ah Im; Han Suk Ryu; Won Hwa Kim; Jung Min Chang; Nariya Cho; Woo Kyung Moon; Gi Jeong Cheon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-21       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.